Trial Profile
Phase II Trial of Durvalumab (MEDI4736) Maintenance Therapy After Concurrent Chemoradiation Therapy With Durvalumab (MEDI4736) for Limited Disease-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 28 Apr 2022 Results published in the European Journal of Cancer
- 27 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2018 New trial record